CDSCO approves antibody cocktail drug for restricted emergency use to treat mild Covid-19 cases
CDSCO approves use of antibodies cocktail drug (Casirivimab and Imdevimab) for restricted emergency use to treat mild to moderate Covid-19 in adults and paediatric patients.
advertisement
Health workers inspect Covid-19 patients at a hospital in New Delhi. (Photo credit: PTI).
The Indian regulatory body, Central Drugs Standards Control Organisation (CDSCO), has approved the use of antibodies cocktail drug (Casirivimab and Imdevimab), for restricted emergency used to treat mild to moderate Covid-19 in adults and paediatric patients (12 years or weighing more than at least 40 kg).
Antibodies Cocktail Drug can be a game-changer in Covid-19 treatment, especially when these are recommended to be given at the early stages of laboratory-confirmed SARS-CoV-2 infection positive result. Theis is preferebly administered within 10 days of symptoms onset.
This emergency use authorisation (EUA) will now enable Roche to import the globally manufactured product batches to India and will be marketed as well as distributed in India through a strategic partnership with Cipla Limited.
Why is Gautam Gambhir stocking Fabiflu?
The East Delhi MP is handing out the Covid drug at his discretion rather than giving it to hospitals.
25 Apr, 2021
As relatives of Covid patients are forced to run around Delhi for Fabiflu because hospitals and pharmacies have run out of the drug, which is used to treat some Covid patients, East Delhi MP Gautam Gambhir of the BJP is sitting on a stock and handing it out at his discretion.
Why isn t he giving it to hospitals instead, saving patients critical time and their relatives the agony of having to wait outside his door for hours? Who is he giving it to and how?
Coronavirus: COVID-19 cases have been rising in Delhi
New Delhi:
The Delhi government has listed 30 sites from where one can get the anti-viral drug remdesivir for critical COVID-19 patients. The Delhi Police have been asked to provide good security at these sites.
Remdesivir being an investigational therapy drug is given in acute and severe versions of Covid where oxygen support is a must, the centre has said.
The centre has also mapped manufacturers of remdesivir with 19 states that have high Covid case burden. This will ensure smooth and fast delivery of the medicine, the centre said in a statement. Delhi is in one of the 19 states that will get this allocation.